W. Bradford Smith notified Ocular Therapeutix, Inc. on March 20, 2017 of his resignation from his position as Chief Financial Officer of the company, effective March 31, 2017, to pursue other opportunities. Mr. Smith has agreed to provide consulting services on an as needed hourly basis to the company through May 31, 2017 to assist with the transition to a successor. In connection with the departure of Mr. Smith, James Fortune, the company's Chief Operating Officer, will assume the roles of principal financial officer and principal accounting officer on an interim basis, effective April 1, 2017.

Mr. Fortune, age 58, has served as the company's Chief Operating Officer since 2008. Mr. Fortune also served as the Chief Operating Officer of Augmenix, Inc. from 2008 to April 2014 and of AccessClosure, Inc. from 2008 to 2010. Prior to joining the company, Mr. Fortune served as the Chief Operating Officer of Confluent Surgical, Inc.